EUCTR2006-000692-15-GB进行中（未招募）1 期
A prospective single centre, open label, pilot study to evaluate the safety of ICXP007 plus standard of care, for the treatment of lower extremity chronic, neuropathic diabetic foot ulcers - DFU I
Intercytex0 个研究点目标入组 15 人开始时间: 2006年4月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed IRB approved informed consent obtained prior to the first study intervention.
- •2. Age equal to or greater than 40 and less than 85 years old at the time the informed consent is signed.
- •3. Subjects will have a diabetic ulcer on the lower extremity, with the ulcer having all of the following characteristics:
- •a. Full-thickness plantar ulcers.
- •b. Non-infected as determined by clinical assessment.
- •c. Neuropathic as determined by neuro disability score 6 or more.
- •d. Area greater than or equal to 1.0 cm squared and less than or equal to 20.0 cm squared post debridement.
- •e. Has been present for at least 4 weeks under observation at the time of enrollment.
- •f. Extends through the dermis but without tendon, muslce, capsule or bone exposure.
- •4. Subjects will have either insulin-dependent or non-insulin-dependent diabetes mellitus with a HbA1c value in the range of 6% to 12%.
- •5. The ulcer bed at the time of enrollment must be free of all necrotic and infected soft and bony tissue as determined by clinical examination (no evidence of probing to bone).
- •6. Ankle-brachial systolic pressure index greater than 0.7 and palpable foot pulses.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Malignant or connective tissue disease.
- •2. Individuals who have received short course corticosteriods within 30 days, or oral or parenteral chronic immunosupressants within 90 days prior to treatment.
- •3. Individuals with a known hypersensitivity to Aprotinin or any other constituents of Tisseel VH S/D TM i.e. Fibrinogen (human), thrombin (human) and calcium chloride, bovine and porcine products.
- •4. Individuals who have a target ulcer which shows signs of clinical infection as determined by clinical examination.
- •5. Active febrile illness (fever greater than or equal to 38.0 degrees centigrade)
- •6. Renal or liver impairment as indicated by serum creatinine levels and liver function tests three or more times higher than normal values.
- •7. Subject has an active Charcot as determined by clinical examination (new local pain, evidence of swelling and warmth).
- •8. Subjects who refuse or who are unable to participate in all screening procedures, or to comply with the requirements of the study.
- •9. Use of other investigational products at the time of enrolment or during the study.
- •10. The use of any topical treatments, other than SOC, in or on the surface of the target ulcer at the time of enrolment.
- •11. Subjects who have been enrolled in any investigational clinical trial within 30 days of the screening visit.
- •12. Recent or current history of alcohol or drug abuse.
- •13. Females who are pregnant, lactating, or who have not reached menopause and are not abstinent or practising an acceptable means of birth control as determined by the investigator for the duration of the study.
- •14. Subjects who have critical limb ischemia.
研究者
相似试验
进行中（未招募）
1 期
A pilot study to assess the efficacy and safety of OBE2109 in subjects with uterine adenomyosis.EUCTR2017-004042-14-FRObsEva SA9
进行中（未招募）
1 期
A pilot study to assess the efficacy and safety of OBE2109 in subjects with rectovaginal endometriosis.EUCTR2017-004043-21-FRObsEva SA9
尚未招募
不适用
The accuracy of 99mTc-PSMA imaging in the re-staging and response monitoring in patients with metastatic prostate cancerCancer - ProstateMetastatic prostate cancerACTRN12622001030763Fiona Stanley Hospital20
尚未招募
不适用
A study to find out the effect and safety of Amlapitta Mishran Suspension in patients with gastritis (stomach inflammation).CTRI/2020/02/023224Shree Dhootapapeshwar Limited
已完成
不适用
A Clinical study to determine whether RESOLV® Endoscopic Hemostat System is safe and effective at achieving hemostasis (stopping bleeding) in adult subjects diagnosed with non-variceal gastrointestinal bleeding (bleeding from just past your throat to just past your stomach).CTRI/2021/12/038478Hemostasis LLC61